Search Results
Results found for "Bryan L. Roth"
- Innovative Data-Driven Solutions: The pHSense Revolution
They learned how to fine-tune both brightness and fluorescence lifetime.
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
Instead of chasing linear progress, Eric encourages young scientists to stay playful longerâembracing both
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
activation of cytosolic effector proteins: the G proteins after which GPCRs are named, and arrestins which both points of contact it is possible not only to strongly increase binding affinity but also to fine tune both transmembrane domain providing significantly increased binding affinity and providing a means to control both Both properties enable enhanced ligands to avoid being eliminated during the stringent washing process at killing cells than unconjugated MMAE, the Orion CCL5 superagonist analog significantly increased both
- Involvement of various chemokine/chemokine receptor axes in trafficking and oriented locomotion ...
chemokine receptor axes play a pivotal role in the recruitment and oriented trafficking of immune cells both
- Melatonin MT 2 receptor is expressed and potentiates contraction in human airway smooth muscle
mediated via its specific G protein-coupled receptors (GPCRs) named the MT1 receptor, which couples to both
- Purpose-Driven Opioid Research: Catherine Demeryâs Academic Path
For Catherine, it became bothâafter years of uncertainty, pivots, and practical lab experience that grounded
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
quantitative window into tissue partitioning Drugs that sequester into adipose or specialized tissues alter both
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
Join before year-end to secure both. đ Â Join Terry's Corner Before Dec 31st, 2025 đ§ Dr.
- Predicting GPCR Function: Inside the Carlsson Labâs Modeling Toolbox
The lab has witnessed both spectacular accuracy and puzzling failures.
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
Lessons From the Front Lines of Biotech Ajayâs experience in both early-stage biotech and academic science
- Your GPCR Program Decisions Depend on Good Data Interpretation
Katerina Leftheris : New technologies overcoming peptide limitations with insights from both pharma and
- When January Looks Different by March: Orthosteric vs. Allosteric Insights from Our Latest AMA
Probe dependence reveals hidden selectivity and efficacy shifts It becomes critical in both screening
- Decoding Schild Analysis: The Pharmacologistâs Lens on Competitive Antagonism
The modelâs flexibility accommodates both agonism and antagonism as long as the analysis targets equilibrium
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Both orphan and well-characterized GPCRs are untapped opportunities for drug development targeting CNS
- Why Opposing Processes Matter for Your Next GPCR Drug
Constitutive Activity: When Doing Nothing Still Does Something Some GPCRs simply refuse to stay quiet
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
localization, trafficking, and dynamicsâif your probes preserve function, minimize phototoxicity, and work in both
- đ° GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
Check out whatâs coming in September and October: Sign up for both courses now and score a 25% early
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
suppresses inhalation while xylazine prolongs exhalation, creating a respiratory cycle that collapses from both
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
diabetic models have shown that although exendin-P5 induces lower insulin release compared to exendin, both
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
When both disciplines collaborate effectively, pharmacology data becomes a roadmap that guides molecular
- The Hidden Cost of Ambition in Biotech Leadership
The CEO Decision Filters That Protect Both Focus and Biotech Fundraising đ Strategic discipline becomes
- đ° GPCR Weekly News, August 28 to September 3, 2023
stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling CCR7 acts as both
- Therapeutic validation of an orphan G proteinâcoupled receptor
GPR84 is a promising target to exploit and the investment in better tools to study its function in both
- đ° Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
Patients with Acute Burn Injuries Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
- đą Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Become a Premium Member to access both courses at a reduced price.
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
Clear intellectual property builds confidence on both sides of the biotech fundraising table Why biotech
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Discovery programs rarely fail because a molecule âdid nothing.â
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
Both BERKY and ONE-GO biosensors are engineered to detect the GTP-bound Gα subunit, serving as a proxy
- Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial ...
Both can result in a positive inotropic effect.






















